山东地区非小细胞肺癌分子靶向治疗驱动基因表达情况及临床特征分析

发布时间：2018-08-18 15:12

【摘要】：背景与目的分子生物学靶向治疗已逐渐成为非小细胞肺癌(non-small cell lung cancer,NSCLC)的一个重要治疗手段,本研究通过分析山东地区NSCLC多种驱动基因表达情况及临床病理特征,为筛选分子靶向治疗目标人群提供理论依据。方法采用荧光探针PCR法检测表皮生长因子受体(epidermal growth factor receptor,EGFR)、棘皮动物微管相关蛋白4-间变性淋巴瘤激酶(echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase,EML4-ALK)、肉瘤致癌因子-受体酪氨酸激酶(ROS proto-oncogene 1,receptor tyrosine kinase,ROS1)、鼠类肉瘤病毒癌基因(Kirsten rat sarcoma viral oncgene,KRAS)基因表达情况,回顾性分析阳性病例的临床病理特征。结果 EGFR基因突变阳性率为36.70%,主要为19、21外显子突变,突变人群主要为女性、腺癌、不吸烟患者,组间差异有统计学意义。EML4-ALK融合基因重排阳性率为9.37%。人群特征主要为60岁以下不吸烟人群,组间差异有统计学意义,基因突变与病理类型和性别间无明显差异。ROS1融合基因重排阳性率为3.67%,均为60岁以下患者,组间差异有统计学意义。23份病例标本开展KRAS基因检测,阳性标本数2例,阳性率为8.70%。2份阳性标本均为60岁以上病例,男女各占1例,病理类型均为腺癌,均无吸烟史。此外,未发现有两种基因同时突变的病例。结论 EGFR、EML4-ALK、ROS1、KARS基因在NSCLC患者中存在较高的突变率,且具有不同的人群特征,在选择靶向治疗人群中具有重要意义。
[Abstract]:Background & objective Molecular biological targeted therapy has gradually become an important treatment for non-small cell lung cancerous NSCLC. This study analyzed the expression and clinicopathological characteristics of multiple driving genes of NSCLC in Shandong province. To provide theoretical basis for screening molecular targeted therapy target population. Methods Epidermal growth factor receptor (epidermal growth factor receptor EGFR, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase- EML4-ALK, ROS proto-oncogene 1 receptor tyrosine kinase ROS1, mice were detected by fluorescence probe PCR method. Expression of sarcoma virus oncgene (Kirsten rat sarcoma viral oncgene KRAS, The clinicopathological features of positive cases were retrospectively analyzed. Results the positive rate of EGFR gene mutation was 36.70%, mainly in exon 1921. The mutation population was mainly female, adenocarcinoma and non-smoking patients. The positive rate of EML4-ALK fusion gene rearrangement was 9.37%. There was no significant difference in gene mutation with pathological type and sex. The positive rate of fusion gene rearrangement of ROS1 was 3.67, all of them were under 60 years old. The difference was statistically significant. The KRAS gene was detected in 23 cases. The positive rate was 8.70.2. The positive rate was 8.70.2 cases over 60 years old, male and female accounted for 1 case, the pathological type was adenocarcinoma, and none of them had a history of smoking. In addition, there were no cases in which two genes were mutated at the same time. Conclusion EGFRN EML4-ALKFROS1KARS gene has a high mutation rate in NSCLC patients and has different population characteristics, which is of great significance in the selection of targeted therapy population.
【作者单位】：济南大学山东省医学科学院医学与生命科学学院;山东省肿瘤医院山东省医学科学院;
【分类号】：R734.2

【相似文献】